A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalization

Globalization and Health

Volumn 5, Issue , 2009, Pages

  Young, Fiona ^a   Critchley, Julia A ^a   Johnstone, Lucy K ^a   Unwin, Nigel C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77953710853     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-5-9     Document Type: Review

References (88)

1. WHO The Global Burden of Disease: 2004 update. Switzerland 2004, WHO.
2. Hadley C. The infection connection: Helicobacter pylori is more than just the cause of gastric ulcers-it offers an unprecedented opportunity to study changes in human microecology and the nature of chronic disease. EMBO rep 2006, 7(5):470-473. 10.1007/s00125-006-0208-5, 1479565, 16670677.
3. McNally R, Feltbower R, Parker L, Bodansky H, Campbell F, McKinney P. Space-time clustering analyses of type 1 diabetes among 0- to 29-year-olds in Yorkshire, UK. Diabetologia 2006, 49(5):900-904. 10.1086/519841, 16557371.
4. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, Nelwan RH, Parwati I, Meer JW, van Crevel R. The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Diseases 2007, 45(4):428-435. 10.1159/000050578, 17638189.
5. Bacakoglu F, Basoglu O, Cok G, Sayiner A, Ates M. Pulmonary Tuberculosis in Patients with Diabetes mellitus. Respiration 2001, 68:595-600. 10.1210/jc.2002-020794, 11786714.
6. Chen D, Misra A. Lipodystrophy in human immunodeficiency virus-infected patients. The Journal of Clinical Endocrinology and Metabolism 2002, 87(11):4845-4856. 10.1210/jc.2002-020794, 12414837.
7. Falasca K, Ucciferri C, Manzoli L, Mancino P, Pizzigallo E, Conti P, Vecchiet J. Metabolic Syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol 2007, 20(3):519-527. 10.1038/ncpendmet0587, 17880765.
8. Falutz J. Therapy insight:body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Prac Endocrinol Metab 2007, 3(9):651-661.
9. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. New England Journal of Medicine 2005, 352(1):48-62. 10.1371/journal.pmed.0050152, 15635112.
10. Jeon C, Murray M. Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies. PLoS Med 2008, 5(7):e152. 10.1007/s11883-008-0010-6, 2459204,2459204, 18630984.
11. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 2008, 10(1):61-70. 10.1177/1742395307081502, 18366987.
12. Stevenson CR, Critchley JA, Forouhi NG, Roglic G, Williams BG, Dye C, Unwin NC. Diabetes and the risk of tuberculosis: a neglected threat to public health?. Chronic Illness 2007, 3(3):228-245. 10.1177/1742395307081502, 18083679.
13. Tamura M, Shirayama R, Kasahara R. A study on relation between active pulmonary tuberculosis and underlying diseases. Kekkaku 2001, 76:619-624. 10.1016/0041-3879(90)90040-F, 11676119.
14. Mugusi F, Swai AB, Alberti KG, Melarty G. Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle 1990, 71(4):271-276. 10.1016/0041-3879(90)90010-6, 2267680.
15. Oluboyo PO, Erasmus RT. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle 1990, 71:135-138. 10.1186/1471-2458-7-234, 2219464.
16. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, Unwin NC. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007, 7:234. 10.1111/j.1742-1241.2006.01267.x, 2001194, 17822539.
17. Aboud M, Elgalib A, Kulasegaram R, Peters B. Insulin Resistance and HIV infection: a review. International Journal of Clinical Practice 2007, 61(3):463-472. 10.1097/00002030-199807000-00003, 17313615.
18. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm D, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-F58. 10.1097/00002030-199807000-00003, 9619798.
19. Morton R, . (Ed) Phthisiolgia: or a treatise of consumptions 1694, London: Smith and Walford, (Ed).
20. Brock BL. The diabetic patient with tuberculosis. Lancet 1957, 77:238-242.
21. Ferrara MA. The tuberculous diabetic patient. N Engl J Med 1952, 246(2):55-56.
22. UK Department of Health Stopping tuberculosis in England: an action plan from the chief Medical Officer. 2004, COI Communications for the Department of Health, Gateway ref: 1176, UK Department of Health.
23. The STOP TB Partnership Stop TB Partnership and World Health Organization. Global Plan to Stop TB 2006-2015 2006, World Health Organization, Switzerland, The STOP TB Partnership.
24. Tuberculosis Coalition for Technical Assistance International standards for Tuberculosis care (ISTC). 2006, The Hague: Tuberculosis Coalition for Technical Assistance, Tuberculosis Coalition for Technical Assistance.
25. UN The Millennium Development Goals Report 2007. 2007, United Nations Department of Economic and Social Affairs (DESA), UN.
26. WHO report Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland 2008, WHO report.
27. Alisjahbana B, van Crevel R, Sahiratmadja E, den Heijer M, Maya A. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis 2006, 10:696-700.
28. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997, 87(4):574-579. 10.2337/diacare.27.7.1584, 1380835, 9146434.
29. Perez A, Brown HS, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg 2006, 74:604-611. 10.1017/S0950268806006935, 1464139, 16606993.
30. Ponce-De-Leon A, Garcia-Garcia L, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Gustavo O, Rojas R, Ferreyra-Reyes L, Cano-Arellano B, Bobadilla M, et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care 2004, 27:1584-1590. 10.1007/BF02148551, 15220232.
31. Restrepo BI, Fisher-Hoch SP, Crespo JG, Whitney E, Perez A, Smith B, McCormick JB. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect 2007, 135(3):483-491. 10.1017/S0950268806006935, 16863600.
32. Englebach K. Passagerer Diabetes Mellitus bei 2 Tuberkulosekranken. [Transitory diabetes mellitus in two tuberculotics.]. Journal Beitr Klin Tuberk Spezif Tuberkuloseforsch 1954, 110(5):470-473.
33. Nichols GP. Diabetes among young tuberculous patients; a review of the association of the two diseases. Am Rev Tuberc 1957, 76(6):1016-1030. 10.1111/j.1574-695X.1999.tb01397.x, 13488012.
34. Karachunski MA, Iakovleva OB, Belglarian MP. Clinical aspects of pulmonary tuberculosis in patients with borderline disorder of carbohydrate metabolism. Probl Tuberk 1993, 10:16-17.
35. Joint Formulary Committee, British National Formulary, British Medical Association, Royal Pharmaceutical Society of Great Britain British National Formulary 2008, 56. London: BMJ and RPS, Joint Formulary Committee, British National Formulary, British Medical Association, Royal Pharmaceutical Society of Great Britain.
36. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunolo Med Microbiol 1999, 26(3-4):259-265.
37. Prud'homme GJ, Fuks A, Colle E, Seemayer TA, Guttmann RD. Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages. J Exp Med 1984, 159(2):463-478. 2187220, 6607315, 10.1084/jem.159.2.463.
38. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med 1982, 72:439-450. 1, 7036735.
39. Tsukaguchi K, Yoneda T, Yoshikawa M. Case study of interleukin-1 beta, tumor necrosis factor alpha and interleukin-6 production by peripheral blood monocytes in patients with diabetes mellitus complicated by pulmonary tuberculosis. Kekkaku 1992, 67(12):755-760.
40. Janeway C, Travers P, Walport M, Shlomchik M. Immunobiology: The immune system in health and disease 2004, 6. Garland Science, New York.
41. Madigan M, Martinko J, Parker J. Brock Biology of Microorganisms. 2002, 10. Pearson Education, London.
42. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, Restrepo BI, . Trackers. TNST Type 2 diabetes and multidrug-resistant tuberculosis. Scandinavian Journal of Infectious Diseases 2008, 40(11 & 12):888-893. 10.1080/00365540802342372, 18728934, Trackers. TNST.
43. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Infect Dis Clin North Am J Med 1995, 9:65-96.
44. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005, 48(7):1247-1257. 10.1007/s00125-005-1802-7, 15971062.
45. Ramachandran G, Santha T, Garg R, Baskaran D, Iliayas SA, Venkatesan P, Fathima R, Narayanan PR. Vitamin A levels in sputum-positive pulmonary tuberculosis patients in comparison with household contacts and healthy 'normals'. The International Journal of Tuberculosis and Lung Disease 2004, 8:1130-1133.
46. Vijayamalini M, Manoharan S. Lipid peroxidation, vitamins C, E and reduced glutathione levels in patients with pulmonary tuberculosis. Cell Biochem Funct 2004, 22(1):19-22. 10.1002/cbf.1039, 14695649.
47. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Br J Nutr 2003, 89:552-572. 10.1079/BJN2003837, 12720576.
48. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27(3):813-823. 10.2337/diacare.27.3.813, 14988310.
49. Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002, 6:1114-1117.
50. Patel JC, De Souza C, Jigjini SS. Diabetes and tuberculosis. Indian Journal of Tuberculosis 1977, 24(4):155-158.
51. Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis 2003, 7(1):58-64.
52. Sosman MC, Steidl JH. Diabetic tuberculosis. Am J Roentgenol 1927, 17:625.
53. Martens GW, Arikan MC, Lee J, Ren F, Greiner D. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol 2007, 37:518-524. 2048677, 17585110, 10.1165/rcmb.2006-0478OC.
54. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43(7):848-854. 10.1086/507543, 16941365.
55. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
56. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S, 9686693.
57. The IDF consensus worldwide definition of the Metabolis Syndrome. , http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
58. Chen LF, Hoy J, Lewin SR. Ten years of highly active therapy for HIV infection. Med J Aust 2007, 186(3):146-151.
59. Mallal SA, John M. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309-1316. 10.1097/00002030-200007070-00002, 10930144.
60. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997, 350:1596. 10.1016/S0140-6736(05)64011-1, 9393341.
61. Note R, Maisonneuve C, Letteron P, Peytavin G, Djouadi F, Igoudjil A, Guimont M-C, Biour M, Pessayre D, Fromenty B. Mitochondrial and Metabolic Effects of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Mice Receiving One of Five Single- and Three Dual-NRTI Treatments. Antimicrob Agents Chemother 2003, 47(11):3384-3392. 253807, 14576092, 10.1128/AAC.47.11.3384-3392.2003.
62. Gervasoni C, Ridolfo AL, Trifirò G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, Moroni M. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13(4):465-471. 10.1097/00002030-199903110-00004, 10197374.
63. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). J Acquir Immune Defic Syndr 2005, 40:119-120. 10.1097/01.qai.0000187137.34789.dd, 16186727.
64. Moreno SA, Martinez EB. Lipodystrophy and long-term therapy with nucleoside reverse transcriptase inhibitors. AIDS 2000, 14(7):905-906. 10.1097/00002030-200005050-00024, 10839605.
65. Wohl DA. Considering metabolic issues when initiating HIV therapy. Current HIV/AIDS Reports 2007, 4:119-125. 10.1007/s11904-007-0018-5, 17883997.
66. Fève B, Glorian M, Hadri KE. Pathophysiology of the HIV-Associated Lipodystrophy Syndrome. Metab Syndr Relat Disord 2004, 2(4):274-286. 10.1089/met.2004.2.274, 18370696.
67. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998, 1(11):1393-1394.
68. Grunfeld C. Insulin Resistance in HIV infection: drugs, host responses, or restoration to health?. Topics in HIV Medicine 2008, 16(2):89-93.
69. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin 2008, 24(3):609-624. 10.1185/030079908X272742, 18208641.
70. Blümer R, van Vonderen M, Sutinen J, Hassink E, Ackermans M, van Agtmael M, Yki-Jarvinen H, Danner S, Reiss P, Sauerwein H. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008, 22(2):227-236. 10.1097/QAD.0b013e3282f33557, 18097225.
71. Magula NP, Mayosi BM. Cardiac involvement in HIV-infected people living in Africa: a review. Cardiovasc J S Afr 2003, 14:231-237.
72. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004, 109:1349-1353. 10.1161/01.CIR.0000120707.98922.E3, 15023871.
73. Dye C. Global epidemiology of tuberculosis. Lancet 2006, 367:938-940. 10.1016/S0140-6736(06)68384-0, 16546542.
74. International Diabetes Federation Diabetes Atlas 2006, 3, International Diabetes Federation., http://www.eatlas.idf.org/
75. 2007 AIDS Epidemic Update. Chapter two overview of the global AIDS epidemic. , http://data.unaids.org/pub/GlobalReport/2006/2006_GR_CH02_en.pdf
76. Unwin NC, Alberti KG. Diabetes and the good, the bad and the ugly of globalization. Int Diabetes Monitor 2007, 19(3):6-11.
77. United Nations Population Division UN An overview of urbanization, internal migration, population distribution and development in the world. 2008, UN, New York, United Nations Population Division UN.
78. UN-HABITAT State of the World's Cities: Trends in Sub-Saharan Africa. 2004, UN-HABITAT. Nairobi, UN-HABITAT.
79. Unwin N, Alberti KG. Chronic non-communicable diseases. Annals of Tropical Medicine & Parasitology 2006, 100(5-6):455-464.
80. Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in sub-Saharan Africa. Circulation 2005, 112(23):3592-3601. 10.1161/CIRCULATIONAHA.105.544312, 16330701.
81. Sobngwi E, Mbanya JC, Unwin NC, Porcher R, Kengne AP, Fezeu L, Minkoulou EM, Tournoux C, Gautier JF, Aspray TJ, et al. Exposure over the life course to an urban environment and its relation with obesity, diabetes, and hypertension in rural and urban Cameroon. Int J Epidemiol 2004, 33(4):769-776. 10.1093/ije/dyh044, 15166209.
82. Hawkes C. The role of foreign direct investment in the nutrition transition. Public Health Nutrition 2005, 8(4):357-365. 10.1079/PHN2004706, 15975180.
83. Drewnowski A, Popkin BM. The nutrition transition: new trends in the global diet. Nutrition Reviews 1997, 55(2D97A):31-43.
84. Mbanya JC, Ngogang J, Salah JN, Minkoulou E, Balkau B. Prevalence of NIDDM and Impaired Glucose Tolerance in a Rural and an Urban Population in Cameroon. Diabetologia 1997, 40:824-829. 10.1007/s001250050755, 9243104.
85. Aspray TJ, Mugusi F, Rashid S, Whiting D, Edwards R, Alberti KG, Unwin NC. Essential Non-Communicable Disease Health Intervention Project. Rural and urban differences in diabetes prevalence in Tanzania: the role of obesity, physical inactivity and urban living. Trans R Soc Trop Med Hyg 2000, 94(6):637-644. 10.1016/S0035-9203(00)90216-5, 11198647.
86. Organization for Economic Co-operation and Development Database on immigrants and expatriates. 2005, Paris: OECD, Organization for Economic Co-operation and Development.
87. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary. Clinical Infectious Diseases 2007, 44(7):981-987. 10.1086/512371, 17342654.
88. Akokpari J. Globalisation and Migration in Africa. African Sociological Review 2000, 4(2):72-92.